265 related articles for article (PubMed ID: 27600985)
1. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.
Pascual J; Royuela A; Fernández AM; Herrero I; Delgado JF; Solé A; Guirado L; Serrano T; de la Torre-Cisneros J; Moreno A; Cordero E; Gallego R; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2016 Dec; 18(6):819-831. PubMed ID: 27600985
[TBL] [Abstract][Full Text] [Related]
2. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
Fine NM; Kushwaha SS
Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
[TBL] [Abstract][Full Text] [Related]
4. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Bhat M; Watt KD
Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
Rittà M; Costa C; Solidoro P; Sidoti F; Libertucci D; Boffini M; Rinaldi M; Baldi S; Cavallo R
Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
[TBL] [Abstract][Full Text] [Related]
7. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature.
Bowman LJ; Brueckner AJ; Doligalski CT
Transplantation; 2018 Feb; 102(2S Suppl 1):S50-S59. PubMed ID: 29369973
[TBL] [Abstract][Full Text] [Related]
8. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.
Brennan DC; Aguado JM; Potena L; Jardine AG; Legendre C; Säemann MD; Mueller NJ; Merville P; Emery V; Nashan B
Rev Med Virol; 2013 Mar; 23(2):97-125. PubMed ID: 23165654
[TBL] [Abstract][Full Text] [Related]
9. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
Andrassy J; Hoffmann VS; Rentsch M; Stangl M; Habicht A; Meiser B; Fischereder M; Jauch KW; Guba M
Transplantation; 2012 Dec; 94(12):1208-17. PubMed ID: 23269449
[TBL] [Abstract][Full Text] [Related]
10. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
[TBL] [Abstract][Full Text] [Related]
11. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
12. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
Malvezzi P; Jouve T; Rostaing L
Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
[TBL] [Abstract][Full Text] [Related]
13. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
14. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
Fisher RA
Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
[TBL] [Abstract][Full Text] [Related]
16. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.
Sabé N; González-Costello J; Rama I; Niubó J; Bodro M; Roca J; Cruzado JM; Manito N; Carratalà J
Transpl Int; 2012 Jul; 25(7):e78-82. PubMed ID: 22574951
[TBL] [Abstract][Full Text] [Related]
17. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
Kowalsky S; Arnon R; Posada R
Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous infections from viral sources in solid organ transplant recipients.
Ilyas M; Maganty N; Sharma A
J Clin Virol; 2017 Dec; 97():33-37. PubMed ID: 29096391
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
Holdaas H; Potena L; Saliba F
Transplant Rev (Orlando); 2015 Apr; 29(2):93-102. PubMed ID: 25227328
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
